Lung Cancer Diagnostics Industry Market 2017 Expected huge Growth by 2022 Including Opportunities and Approaches

Medical organizations as well as leaders in the global pharmaceuticals industry are stepping up their efforts towards development of profound diagnosis for lung cancer. Rising number of deaths caused by lung cancer is taking a toll on governments as people are demanding precision diagnosis and a cure-all for this terminal disease. In a bid to adapt to the urban rat race, millions of consumers have adopted lifestyles that are stemming the occurrence of lung cancer. For public administration authorities, compelling people to avoid such lifestyles is like challenging the status quo. The burden of controlling the incidence of lung cancer gets passed on to hospitals & medical research organizations as they strive to develop novel diagnostic and therapeutic procedures.

Key players in the Global Lung Cancer Diagnostics Market are collaborating with regional health ministries and medical administrators for gauging the impact of therapeutic diagnosis on lung cancer patients. Such cooperative efforts are of paramount importance in the global lung cancer diagnostics market, where overlooking the plausible aftereffects of diagnostic procedures can cost lives.

Request Free Sample Report Here – https://www.factmr.com/connectus/sample?flag=S&rep_id=49

Lung cancer or lung carcinoma is malignant maturation of lung tumor, caused by uncontrolled growth of cells & tissues in the lung. Lung cancer diagnostics can be defined as an umbrella of tests & diagnosis procedures used in treatment of lung cancer, which includes methods such as imaging, tumor screening, sputum cytology tests, and biopsy.

The growth of the global market for lung cancer diagnostics is primarily attributed to increasing developments in lung cancer-specific biomarkers. These diagnostic tools are expected to facilitate personalized treatment approach towards lung malignancies. A number of biomarkers exist in the research pipeline. In the recent past, Epigenomics AG launched a new test based on blood utilizing DNA methylation biomarkers, whose developments are in the process. The initial results obtained from these tests have promised early diagnosis of lung cancer. Such incidences are expected to increase demand for lung cancer diagnostics across the globe.

A number of awareness programs associated with lung cancer and its related symptoms have been initiated in order to enhance the diagnosis and screening rates of individuals with high risks of developing lung malignancies. For example – In the United Kingdom, November is considered to be the lung cancer awareness month, and is supported by Roy Castle Lung Cancer Foundation. Such initiatives help in raising awareness about early detection and diagnosis of lung cancer.

CA tests will continue to be the most lucrative tests for lung cancer diagnostics in the market. Revenue from CA tests will account for US$ 889.3 Mn by 2022-end. Angiogenesis inhibitor is expected to witness the fastest expansion among test type in the market, followed by HER 2 tests. Revenue from ALK tests for lung cancer diagnostics will continue to remain low in the market.

Browse Complete Report In-Depth Here – https://www.factmr.com/report/49/lung-cancer-diagnostics-market

Hospital-associated labs will remain the most lucrative end-users of lung cancer diagnostics in the global market, with revenues estimated to reach nearly US$ 1,500 Mn by 2022-end. Cancer research institutes will continue to exhibit the fastest expansion in the global lung cancer diagnostics market, followed by independent diagnostic laboratories. In addition, independent diagnostic laboratories are expected to be the second largest end-users of lung cancer diagnostics throughout the forecast period.

On the basis of indication, although non-small cell lung cancer is expected to remain sought-after in the market, small cell-lung cancer is expected to exhibit the fastest expansion through 2022. Revenue from non-small cell lung cancer is expected to remain largest during the forecast period. In contrast, revenue from small cell lung cancer will continue to be low in the global lung cancer diagnostics market.

Competition Tracking

Novel product launches for lung cancer diagnostics is a key strategy adopted by leading players in the global market, in order to increase their product portfolio. FactMR’s report profiles key market players, which include Illumina, Inc., Abbott Laboratories, Thermo Fischer Scientific, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., NanoString Technologies, Inc., Myriad Genetics, Inc., Roche Holding AG, and Danaher Corporation.

Table of Contents

Chapter 1. Global Lung Cancer Diagnostics Market – Executive Summary. 12

Chapter 2. Global Lung Cancer Diagnostics Market Overview. 14

2.1. Introduction. 14

2.1.1. Global Lung Cancer Diagnostics Market Taxonomy. 14

2.1.2. Global Lung Cancer Diagnostics Market Definition. 14

2.2. Global Lung Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022. 15

2.2.1. Global Lung Cancer Diagnostics Market Y-o-Y Growth. 15

2.3. Global Lung Cancer Diagnostics Market Dynamics. 15

2.3.1. Drivers. 15

2.3.2. Restraints. 15

2.3.3. Trends. 16

2.4. Supply Chain. 16

2.5. Key Participants Market Presence (Intensity Map) By Region. 16

Chapter 3. Global Lung Cancer Diagnostics Market Analysis and Forecast By Test Type. 17

3.1. Global Lung Cancer Diagnostics Market Size and Forecast By Test Type, 2012-2022. 17

3.1.1. CA Test Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 17

3.1.1.1. Revenue (US$ Mn) Comparison, By Region. 17

3.1.1.2. Market Share Comparison, By Region. 19

3.1.1.3. Y-o-Y growth Comparison, By Region. 19

3.1.2. HER2 Tests Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 20

3.1.2.1. Revenue (US$ Mn) Comparison, By Region. 20

3.1.2.2. Market Share Comparison, By Region. 22

3.1.2.3. Y-o-Y growth Comparison, By Region. 22

3.1.3. ALK Tests Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 23

3.1.3.1. Revenue (US$ Mn) Comparison, By Region. 23

3.1.3.2. Market Share Comparison, By Region. 25

3.1.3.3. Y-o-Y growth Comparison, By Region. 25

3.1.4. Angiogenesis Inhibitor Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 26

3.1.4.1. Revenue (US$ Mn) Comparison, By Region. 26

3.1.4.2. Market Share Comparison, By Region. 28

3.1.4.3. Y-o-Y growth Comparison, By Region. 28………………………Continued

Buy This Report from Here – https://www.factmr.com/checkout/49/S

About FactMR

FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized Sports market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us –

FactMR
Suite 9884
27 Upper Pembroke Street, Dublin 2, Ireland
Telephone @ +353-1-6111-593
Email: sales@factmr.com
Website: https://www.factmr.com/